SynchroMed Infusion System, Ascenda Intrathecal Catheters
Medtronic, Inc. · Decision date Oct 27, 2026
What did the FDA approve?
FDA records P860004/S458 as a supplement to PMA P860004, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 27, 2026.
FDA approval order statement
software changes to address Z-1506-2025 in the Model A820 (Personal Therapy Manager) Application
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- General Hospital
- Decision date
- Oct 27, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P860004/S458
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- LKK
- Decision code
- APPR
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pump, infusion, implanted, programmable.
- Applicant
- Medtronic, Inc.
- Product code
- LKK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P860004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P860004 · Original PMA
MEDTRONIC(R) SYNCHROMED(TM) PUMP & INFUSION SYSTEM
P860004/S458 received
Application receipt date recorded by FDA.
P860004/S462 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S458 · FDA decision
Normal 180 Day Track
P860004/S464 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters TDD (Drug Delivery Infusion Pump 8667), TDD (Drug Delivery I
P860004/S465 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
Timeline entries are records held by MedtechLedger for P860004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P860004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Mar 14, 1988 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P860004/S458
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
